Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced that CEO Kevin S. Boyle Sr. and VP of Research & Development Drew Deniger will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 9:20am ET. The presentation will be available via a live webcast on the company’s website, with an archived replay accessible for 30 days. Alaunos focuses on oncology cell therapies, developing T-cell receptor therapies using its proprietary Sleeping Beauty gene transfer technology and targeting major tumor-related mutations.

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company’s Chief Executive Officer, Kevin S. Boyle Sr., and Vice President of Research & Development, Drew Deniger, are scheduled to participate in the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 9:20am ET.

A live webcast of the presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at www.alaunos.com. An archived replay of the webcast will be available for approximately 30 days.

About Alaunos Therapeutics, Inc.
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com

FAQ

When is Alaunos Therapeutics presenting at the Oppenheimer Healthcare Conference?

Alaunos Therapeutics will present on March 17, 2022, at 9:20am ET.

Where can I watch the Alaunos Therapeutics presentation?

The presentation can be watched via a live webcast on Alaunos Therapeutics' website under the Investors section.

What is Alaunos Therapeutics' focus in oncology?

Alaunos Therapeutics focuses on developing T-cell receptor therapies targeting common mutations in oncogenic genes.

What technology does Alaunos Therapeutics use for its therapies?

Alaunos utilizes proprietary Sleeping Beauty gene transfer technology for its T-cell receptor therapies.

How long will the Alaunos webcast be available for replay?

The archived replay of the webcast will be available for approximately 30 days.